UK CLL Forum - Virtual Journal Club

Virtual Journal Club

Read selected articles reviewed by the executive committee here (just click on the article to read the review). If you would like to submit a review on a journal article please contact us by emailing CLL@hartleytaylor.co.uk.

'Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.' - Pettitt et al. J Clin Oncol. 2012;30(14):1647-55

'Chronic lymphocytic leukaemia is driven by antigen-independent cell autonomous signaling. Minden et al. Nature. 2012;489:309–312.

'Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia.'
Landau DA et al. Cell 2013;152(4): 714-726.

The genomic landscape of chronic lymphocytic leukemia: clinical implications. Quesada V et al BMC Med. 2013;11:124.

Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Vardi A et al Blood. 2013;121:4521.

Enhancement of CD154/IL4 Proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in CLL. Ahearne et al. BJH 2013 May 27. doi: 10.1111/bjh.12401. [Epub ahead of print]

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. Byrd JC, Furman RR, Coutre SE et al NEJM;June 19, 2013.

Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells
Audun Os, Simone Burgler, Anna ParenteRibes, AneFunderud, Dong Wang, Keith M. Thompson, Geir E. Tjonnfjord, BjarneBogen and Ludvig Munthe. Cell Reports a, 566-577 August 15, 2013.

Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter Syndrome.
Chigrinova E,et al . Blood published on line September 4th 2013.

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukaemia. Furman R.R., Sharman J.P., Coutre, S.E. et al
NEJM; March 13, 2014

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: trial results of the German CLL Study Group
Valentin Goede et al.

Haematologica, published ahead of print, February 28, 2014

Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib. Woyach et al NEJM June 12 2014.

Ibrutinib versus Ofatumumab in Previously Treated ChronicLymphoid Leukemia. JC Byrd et al.
New England Journal of Medicine371;3 July 17, 2014

MicroRNA-155 influences B-cell receptor signalling and associates with aggressive disease in chronic lymphocytic leukemia. Cui B et al. Blood. 2014 Jul 24;124(4):546-54

How does lenalidomide target the chronic lymphocytic leukaemia microenvironment?’
Arnon Kater,Sanne Tonino, Alexander Egle, Alan Ramsay
Blood First Edition Paper, prepublished online August 26 2014; DOI10.1182/blood-2014-05-578286
And
Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21 WAF1/Cip1 -dependent mechanismin dependent of functional p53
Jessie-F.Fecteau, et al BloodSeptember 4 2014

SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Ruth Clifford et al. Blood 2013.

ASH 2014 Review. George Follows, UK CLLForum Chair. Cambridge, UK

Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.

Ojha J et al. Blood. 2015 Jan15;125(3):492-8.

Ibrutinib for previously untreated and relapsed or refractory chroniclymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Mohammed Z H Farooqui et al. Lancet Oncol 2015; 16: 169–76

Ojha, J.,et al. Deep sequencing identi fi es genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia, BLOOD 2015, 125, (3), 492–499

Parrish et al. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular toxicity against chronic lymphocytic leukemia, Leukemia 2015, 29:1799-1810

Complex Karyotype is a StrongerPredictor Than Del(17p) for an Inferior Outcome in Relapsed or RefractoryChronic Lymphocytic Leukemia Patients Treated With Ibrutinib-Based Regimens

Thompson et al, Cancer 2015 Oct 15;121(20):3612-21.

Minimalresidual disease is an independent predictor for 10-year progression-free and overallsurvival in CLL

Marwan Kwok, Andy C.Rawstron, Abraham Varghese, Paul A.S. Evans, Sheila J.M. O’Connor, Chi Doughty,Darren J. Newton, Paul Moreton, Peter Hillmen

Blood. 2016 Oct3.